Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 3/20 | 0.39 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.39 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.39 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.39 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 7/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 4/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3383794 | 0.84 | HDAC4 (0.39) | RENSRCCTSSITGB3ITGA2B | |
| SCHEMBL3386405 | 0.81 | REN (0.43) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| SCHEMBL3386397 | 0.81 | REN (0.43) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| SCHEMBL3384240 | 0.69 | SYK (0.45) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| SCHEMBL3384235 | 0.69 | SYK (0.45) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| SCHEMBL3384237 | 0.69 | SYK (0.45) | PSMB5PSMB1PSMB8PSMB9PSMB10 | |
| SCHEMBL3382125 | 0.68 | MEN1 (0.47) | PSMB5PSMB1PSMB8PSMB9REN | |
| SCHEMBL3382121 | 0.68 | MEN1 (0.47) | PSMB5PSMB1PSMB8PSMB9REN | |
| SCHEMBL3382127 | 0.68 | MEN1 (0.47) | PSMB5PSMB1PSMB8PSMB9REN | |
| SCHEMBL25054179 | 0.68 | CTSK (0.64) | PSMB5CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828974-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20120208784-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8183231-B2 | Substituted propane phosphinic acid derivatives | AVENTIS PHARMACEUTICALS INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-1765850-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | Aventis Pharmaceuticals, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20070060502-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | disclosed |
| WO-2005118618-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060502-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | PHOSPHO1, PTEN, PLCB1 | PSMB5 2558/4885PSMB1 2478/4885PSMB8 4183/4885 |
| US-20120208784-A1 | SUBSTITUTED PROPANE PHOSPHINIC ACID DERIVATIVES | PHOSPHO1, PTEN, PLCB1 | PSMB5 2558/4885PSMB1 2478/4885PSMB8 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.